Gene Therapy for Eye Disease: Approved Treatment, Trials and Limits

Gene therapy can help some people with a precisely identified inherited retinal disorder, but it is not a general cure for blindness. A disease name such as retinitis pigmentosa is not enough to establish eligibility. The relevant gene changes, remaining retinal cells and the exact treatment all matter.

How the approaches differ

Gene addition supplies a working copy of a gene to selected cells, often using an engineered viral vector. Gene editing aims to alter a DNA sequence. Other experimental approaches change how a harmful gene is expressed. These are different technologies with different evidence, delivery methods and risks; the term “gene therapy” does not make their results interchangeable.

What Luxturna is approved to treat

In the United States, Luxturna (voretigene neparvovec-rzyl) is approved for confirmed biallelic RPE65 mutation-associated retinal dystrophy, with viable retinal cells as determined by the treating physician. Biallelic means that both copies of the gene are affected. It is not a treatment for all forms of retinitis pigmentosa (RP) or Leber congenital amaurosis (LCA), which can have other genetic causes.

The treatment supplies a working RPE65 gene; it does not simply replace the whole retina. Potential improvement in useful vision should not be described as guaranteed normal sight or a permanent cure. A retinal specialist must assess likely benefit and limitations for the individual.

What is still being studied?

  • RP and LCA with other causes: research targets particular variants or retinal functions. A result in one genetic subgroup cannot be applied to every patient with the same broad diagnosis.
  • CEP290 gene editing: a 2024 phase 1–2 study treated 14 people with a specific CEP290-associated disorder. Some participants improved on visual-function measures. This small, open-label study supports further research, not a claim of established cure.
  • Wet AMD: approaches such as RGX-314 aim to provide sustained anti-VEGF activity and reduce treatment burden. They are not correcting a single inherited AMD mutation. The phase 3 study NCT05407636 remains research in the cited trial listing; it is not a reason to stop prescribed injections.
  • Choroideremia: a gene-based research strategy must be judged by its trial results, eligibility and regulatory status, not by the promise of the mechanism alone.

Why “one injection” does not mean minor or risk-free

Delivery varies by product. Luxturna is administered beneath the retina by a trained surgeon, with each eye treated separately. Subretinal treatment is not equivalent to a simple surface eye drop. Risks can include inflammation, infection, pressure changes and retinal complications; benefit and safety need follow-up. Ask the specialist to explain both treatment-related and procedure-related risks using the current product information.

A practical route from diagnosis to a treatment discussion

  1. Obtain an examination by an inherited-retinal-disease specialist.
  2. Discuss clinically appropriate testing and genetic counseling. Read what genetic testing can and cannot establish.
  3. Bring the full laboratory report, prior imaging and a timeline of visual changes.
  4. Ask whether an option is approved care or a clinical trial, and whether your variant and retinal findings match its criteria.
  5. Request a written account of visits, aftercare, costs and coverage in your country.

A historical list price is not an individual cost estimate. Treatment availability, reimbursement and regulatory approval differ between countries and can change. There is no reliable timetable promising widespread cures by 2030 or 2040.

Questions to ask about a trial

What is the trial identifier and phase? Is recruitment open at my location? Is there a comparison group? What benefit is uncertain, what follow-up is required, and who covers routine care or complications? A registry entry documents a study; it does not prove effectiveness or guarantee enrollment.

What can help while treatment remains uncertain?

Continue recommended eye care and discuss low-vision rehabilitation, magnification, accessible device settings, mobility training and educational or workplace support. These practical services need not wait for a future therapy. New sudden symptoms still require assessment; see urgent vision-change warning signs.

Sources and review

Reviewed October 28, 2026. General education; surgical eligibility and treatment require assessment by an ophthalmologist.